Dyspnea News and Research

RSS
Dyspnea or dyspnoea or shortness of breath is a debilitating symptom that is the experience of unpleasant or uncomfortable respiratory sensations.

Further Reading

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

FDA approves new treatment for people with hairy cell leukemia

FDA approves new treatment for people with hairy cell leukemia

Eagle Pharmaceuticals completes enrollment of second clinical study to evaluate safety, efficacy of RYANODEX

Eagle Pharmaceuticals completes enrollment of second clinical study to evaluate safety, efficacy of RYANODEX

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

FDA approves first drug for treatment of adult AML patients with specific genetic mutation

FDA approves first drug for treatment of adult AML patients with specific genetic mutation

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Celgene to share new and updated data around novel hematological therapies

Celgene to share new and updated data around novel hematological therapies

FDA grants approval for two drugs administered together to treat aggressive form of thyroid cancer

FDA grants approval for two drugs administered together to treat aggressive form of thyroid cancer

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

Study suggests Tai Chi as low-cost alternative to pulmonary rehabilitation for COPD patients

Study suggests Tai Chi as low-cost alternative to pulmonary rehabilitation for COPD patients

Effective pulmonary rehabilitation for persons with COPD in Germany

Effective pulmonary rehabilitation for persons with COPD in Germany

Survival of transplant candidates found to be better than predicted by BODE score

Survival of transplant candidates found to be better than predicted by BODE score

FDA approves first treatment to reduce risk of NSCLC progression

FDA approves first treatment to reduce risk of NSCLC progression